Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 12 Months Ended 101 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Consolidated Statements Of Operations      
Revenues         
Total         
Operating expenses:      
Amortization & depreciation 606 911 76,349
General and administrative 2,886,710 636,877 12,567,949
Total 2,887,316 637,788 12,644,298
Gain (loss) from operations (2,887,316) (637,788) (12,644,298)
Other income (expense):      
Loss on fair value adjustment - derivatives (448,137)    (448,137)
Gain on sale of fixed asset (4,790)    (4,790)
Interest expense (118,194) (474,455) (1,092,992)
Interest expense - beneficial conversion feature (112,064) (70,000) (182,064)
Total (673,605) (544,455) (1,718,403)
Income (loss) before provision for income taxes (3,560,921) (1,182,243) (14,362,701)
Provision for income tax         
Net income (loss) (3,560,921) (1,182,243) (14,362,701)
Less: Net (income) loss attributable to noncontrolling interest 7,615 80,842 88,457
Net income (loss) attributable to TransBiotec, Inc. $ (3,560,921) $ (1,182,243) $ (14,362,701)
Net income (loss) per share (TransBiotec, Inc.)      
(Basic and fully diluted) $ (0.13) $ (0.10)  
Weighted average number of common shares outstanding 28,275,127 11,344,444